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To Ntokozo and Your late Mother 
May the improvement of PMTCT in South Africa 
Always remember that mothers can never be replaced 
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Abstract 
 
Context 
Prevention of mother to child transmission (PMTCT) of HIV relies on identification 
of HIV-positive pregnant women at the first antenatal visit and at time points 
thereafter. As not all women who attend antenatal care initially agree to test or 
maintain an HIV-negative status the lack of re-establishing HIV prevalence at 
delivery may result in missed prevention opportunities and a false impression of 
PMTCT coverage. 
 
Objectives 
To assess whether a routine peri-partum HIV counseling and testing service 
improves access to HIV prevention, testing and care of infants by identifying 
additional HIV-positive women at the time of delivery. 
To assess the effect on the PMTCT coverage indicator when HIV prevalence is re-
established in the delivery population. 
 
Design and Patients 
All women 18 years or older with live births in the labour and postnatal wards of 
the Rahima Moosa Mother and Child Hospital (RMMCH) were interviewed and 
invited to enrol irrespective of their need to retest/test for HIV or their potential 
refusal of an HIV test. Rapid HIV antibody tests were offered to women who had 
no HIV result, reported an HIV-negative result performed more than six weeks 
prior to delivery or reported an HIV result discrepant with her documented result. 
 vi
Test acceptance and HIV prevalence were calculated for the enrolled population. 
The rate of return and results for early infant diagnosis in HIV-exposed infants and 
the follow-up of infected infants were documented. HIV polymerase chain reaction 
(PCR) results for infants not returning to the facility were retrieved from the 
National Health Laboratory Services database. 
 
Results 
Between 9th April 2008 and the 23rd of September 2008 there were 5169 women 
with live births. A total of 3684 (71.3%) of the 5169 women delivering were 
interviewed and 2419 (46.8%) were enrolled. Of the women enrolled, 2140 
(88.5%) reported a known HIV status and 490 (22.9%) of these were HIV-positive. 
After counseling and testing, an additional 101 HIV-positive women were identified 
increasing the number of HIV-positive women by 20.6%. An additional 177 women 
were identified as being HIV-negative. The true infant PMTCT coverage increased 
by 17% as a result of newly identified HIV-positive women. Of 591 HIV-exposed 
infants identified, 284 (48.0%) underwent PCR testing at RMMCH or surrounding 
facilities and 16 (5.6%) tested PCR-positive. Of the infants expected to return to 
RMMCH for PCR testing 155/203 (76.4%) antenataly diagnosed versus 12/83 
(14.5%) newly diagnosed women returned with their infants (p<0.001). Ten HIV-
infected infants were diagnosed at RMMCH of which nine were in care with six 
initiated on antiretrovirals. 
 
 
 
 vii
Conclusion 
A large number of additional HIV-positive mothers were identified by the peri-
partum HIV counseling and testing protocol allowing more infants to access 
prevention however infant follow-up rates were disappointing especially in the 
newly diagnosed group. This approach has the potential to improve delivery of 
PMTCT and knowledge of HIV status in similar clinical settings in South Africa. 
Good documentation of antenatal HIV results and better links between maternal 
and child health services as well as infant feeding counseling need attention. 
Additional support for newly diagnosed HIV-positive women may enhance their 
chances of returning for infant diagnosis and ongoing maternal care.
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Chapter 1 – Introduction 
 
1.1 South Africa in the Context of the Global HIV Pandemic 
 
The prevalence of HIV infection in South Africa is alarming, especially in the 
female population of child-bearing age as it fuels the epidemic in children. At least 
90% of paediatric HIV infections are preventable and as a result of MTCT [1]. The 
annual antenatal maternal prevalence of HIV published by the national DOH is 
shown in Figure 1.1 [2]. 
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Figure 1.1: Annual Antenatal Prevalence – South Africa 1990-2007  
 
Since the birth rate in South Africa is estimated at one million per annum, in 2007 
an estimated 280 000 HIV-exposed infants were born. The exact incidence of 
paediatric HIV in South Africa is currently unknown because the vertical 
transmission rate of HIV is not readily available due to weak information systems. 
Estimates vary between models (Actuarial Society of South Africa and Stats SA) 
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and lie between 23.7% and 30% transmission from mother to child [3, 4]. Without  
the actual vertical transmission in 2007 being known, these models suggest that 
there would have been between 66 000 and 84 000 new infections in the year 
2007. In 2006 it was estimated that about 200 000 to 300 000 children were living 
with HIV [5]. When the global estimates of children living with HIV are examined 
for 2007 (Figure 1.2) [1], the significance of the South African contribution to the 
global paediatric prevalence becomes evident comprising between 270 000 to 370 
000, and making up 14% to 19% of the global two million. 
 
 
Figure 1.2: Number of Children under 15 years of age living with HIV globally 1990-2007 
 
 
1.2 The Impact of HIV on Paediatric and Maternal Care in South Africa 
 
HIV is still the major cause of paediatric and maternal mortality despite the 
availability of effective triple ART [6, 7] and has caused a reversal of the decrease 
in infant and under-5 mortality seen between 1975 and 1994. South Africa 
committed itself to achieving the MDG’s for 2015 in 2000 and goals 4 and 5 aim to 
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achieve reduced maternal and child mortality by 2015, notably a two thirds 
reduction of under-five mortality [8]. Apart from the impact on mortality, the HIV 
epidemic has led to an overwhelming burden on the health care system as well as 
on the morale of health care workers. The management and prevention of 
paediatric and maternal HIV and related mortality is an important part of woman 
and child health in South Africa.  
 
PMTCT should begin prior to pregnancy, as described by the four-pronged 
strategic approach of the World Health Organisation (WHO) [9]: 
 
• Prevent HIV in potential parents (includes emphasis on VCT and 
messages of staying HIV-negative) 
• Prevent unwanted pregnancy (includes family planning and contraception) 
• Prevent HIV transmission to the child 
• Care and support for HIV affected individuals 
 
The South African DOH released the revised PMTCT guidelines on the 11th of 
February 2008 [10]. They incorporate the above points in theory but in practise, 
the South African PMTCT program starts antenataly, omitting the first two prongs 
of the WHO approach which are meant to be addressed through other programs 
(e.g. the VCT program). The South African PMTCT program includes VCT of the 
pregnant woman, counseling regarding feeding choices, prophylactic anti-retroviral 
drugs, free replacement formula feeds for six months if exclusive formula feeding 
is chosen by the mother and a virological HIV test (HIV DNA PCR) on the baby 
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done at six weeks of age. Additional HIV testing is to be performed where an infant 
is breastfed and for all HIV-exposed infants at 18 months of age. 
 
The new protocol has been well received and implementation has begun in all nine 
provinces. The main addition to the sdNVP regimen is AZT given to the pregnant 
woman from 28 weeks of gestation until delivery and then to the baby for one to 
four weeks.  However, successful and reproducible models for implementing this 
program to achieve the NSP target of reducing vertical transmission to <5% by 
2011 are scarce [11].  The PMTCT program is a vital but underutilised tool for 
preventing morbidity and mortality in both women and children and urgently 
requires optimisation. The national uptake of the sdNVP PMTCT protocol before 
the introduction of AZT was thought to be 30% but estimates of uptake vary from 
15% to 78% [5].  
 
Providing pregnant women and infants with antiretroviral prophylaxis has been 
shown since 1993 as an effective intervention (ACT076 trial) [12]. Administering 
sdNVP can achieve almost a 50% reduction in HIV transmission rates [13]. 
Further, there is evidence of transmission under 2% if AZT together with sdNVP is 
used as adopted in the new South African guidelines [14]. Giving sdNVP and AZT 
to the newborn has been demonstrated to be effective, even when only the infant 
receives the dose [15, 16]. As these studies could not ethically have a control arm 
that did not offer any post-exposure prophylaxis, the risk of transmission had to be 
compared with historical reports. In both studies the transmission rate at six to 
eight weeks was around 15% whereas the transmission risk in infants with 
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absolutely no intervention had been reported as 25% at birth with an additional 
16% occurring during breastfeeding [15, 17].  
 
The feeding choices for HIV-infected mothers have been extensively investigated, 
showing that correct feeding techniques, either exclusive breast or formula 
feeding, have protective effects in terms of HIV transmission to infants. Pitfalls in 
poor feeding choices made without adequately considering the AFASS criteria put 
forward by the WHO, have highlighted the significant challenges that face both 
health care workers and mothers in this regard because of the high mortality that 
can be associated with poorly considered exclusive formula feeding [18]. More 
effort is now required to translate lessons learnt into large scale operational 
success. 
 
 
1.3 Access to PMTCT - Maternal Testing 
 
If a pregnant woman is not identified as being HIV-infected, there is currently no 
avenue for her HIV-exposed infant to access the PMTCT program. Furthermore, 
the woman’s chances of accessing HIV treatment are compromised putting her 
ability to function as a caregiver for her child at risk. 
 
Low uptake of PMTCT in South Africa is worrying and increased HIV testing (NSP 
Goal 8) in women is seen as key to improving this situation [11]. Pregnant women 
access the PMTCT program via HIV rapid testing performed during pregnancy 
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usually at the first ANC visit. Retesting during pregnancy and around delivery is 
recommended by the CDC [19], the WHO [20] and is part of the NSP [11] but is 
difficult to implement [21]. Three publications highlight the potential dangers of not 
retesting: refusal of an antenatal HIV test was associated with a high (44%) 
maternal HIV prevalence in Johannesburg [22], seroconversion in late pregnancy 
was around 5% at Chris Hani Baragwanath Hospital [23] and global screening at 
an immunisation service in Kwazulu Natal showed significant discrepancies 
between verbally reported and actual maternal HIV status respectively where 6.7% 
women who reported a negative status were HIV-positive [24]. 
 
The issue of HIV testing during pregnancy has been widely studied since the time 
that HIV was discovered and paediatric AIDS occurred in clinical settings. 
Paediatric AIDS was linked with the virus now known as HIV in 1985 [25] and in 
December 1985 the Mortality and Morbidity Weekly Report (MMWR) of the CDC 
published guidelines for the approach to pregnant women and prevention of 
transmission [26]. In the years following this, these guidelines were expanded with 
the introduction and registration of the first HIV rapid tests to be used in 
pregnancy. Most countries now have extensive PMTCT and HIV testing guidelines 
tailored to suit the country’s population, HIV prevalence and specific needs.  
 
Currently, in South Africa, the HIV status established at the antenatal clinic is not 
written onto the woman’s antenatal card in plain text. It is written as a code using a 
standardised coding mechanism that relies on the first letter of the mother’s name 
and that of her own mother. This code has to be decoded by labour ward and 
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postnatal staff for the mother to be identified as either HIV-positive or negative. 
This system is a controversial issue offering confidentiality of the mother’s HIV 
status but problems with correct decoding and identification of HIV-positive women 
at the various points of care. 
   
The new South African PMTCT policy places an emphasis on routinely offered 
testing for pregnant women. The issue of HIV testing in labour for women who 
were not tested during antenatal care has also been studied extensively, both in 
terms of test-acceptance and impact on efficacy of PMTCT [27, 28]. Essentially 
the emphasis is always to be placed on antenatal testing and repeat testing but for 
those women not identified antenataly for whatever reason, one study concludes: 
”Rapid HIV testing and counseling in labour is a useful practice in high prevalence 
settings” [29]. Testing around the time of labour opens the door for mother-infant 
pairs to access some antiretroviral prophylaxis when there was not that 
opportunity during the pregnancy. If diagnosed pre-delivery there is a chance to 
administer the doses of sdNVP and AZT to the mother and if only diagnosed post-
delivery the baby can be given post-exposure prophylaxis in the form of sdNVP 
and AZT. Evidence has also come to light that the vertical HIV transmission to 
infants from mothers who are unaware of their HIV status is higher than in those 
who know that they are HIV-positive [24]. Maternal HIV infection during late 
pregnancy or during breast feeding may account for up to 40% of infections in 
infants according to a study in Botswana [30]. These are very important findings 
that emphasize the need to prevent HIV in pregnant women and retest during later 
pregnancy and lactation.  
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Loss to follow-up from PMTCT both antenataly and postnataly is a serious 
problem. Manzi et al report a cumulative loss to follow-up of more than 75% 
between initial maternal test and six-month postpartum visit in a district hospital 
setting in Malawi [31]. 
 
Lessons learnt from these studies should be used to develop useful protocols for 
the South African setting. To institute programs it is advisable to establish the 
success of published best practice and experience in large local settings. Should 
such a protocol, tried out in a routine public service setting show similar successes 
one can motivate for its wider spread duplication and adoption in similar settings 
throughout the country. This study thus aims to investigate whether a peri-partum 
HIV testing protocol for women at delivery translates into improved access to 
PMTCT, early testing and treatment of children.  
 
 
1.4 Infant PCR Testing – PMTCT Impact 
   
Apart from addressing whether or not routine counseling and testing identifies 
significant numbers of new women for the PMTCT program, the question of 
whether a routine counseling and testing service identifies additional HIV-exposed 
infants around delivery and translates into a lower transmission rate arises.To 
document a reduced transmission rate following a “post-exposure only” 
intervention, treated infants have to be tested which has proven to be complicated 
by loss to follow-up [32].  
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1.5 Study Setting 
 
1.5.1 History of RMMCH PMTCT Involvement 
 
RMMCH has a history of proactive involvement in the PMTCT program that has 
operated since 1997 [32, 33, 34]. The program at RMMCH offers all the 
components recommended by the South African national PMTCT guidelines. The 
facility has been host to various research protocols and staff members have been 
and are currently active members of provincial and national PMTCT working 
groups. Widely published research includes: 
 
• Early Infant testing research [32, 33] which validates infant PCR testing at 
six weeks of age and shows that it is feasible in low-resource settings to 
both diagnose infants as well as assess PMTCT efficacy   
• Programmatic research on starting women on triple ART during pregnancy 
and other aspects of PMTCT patient flow [34] which highlights that a 
focussed and monitored system of referral from antenatal to ART clinics 
reduces the time pregnant women have to wait for ART initiation 
significantly as well as highlighting the effectiveness of triple ART for 
PMTCT   
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1.5.2 The Obstetric Services at RMMCH 
 
The “catchment area” that the hospital serves is predefined but differs depending 
on the service provided.  
 
1. The RMMCH antenatal clinic functions at two levels each having different 
catchment areas:  
a. It provides primary antenatal care to pregnant women from the 
geographical area surrounding the hospital. 
b. It acts as a secondary level referral centre for high risk women from 
designated surrounding clinics. 
 
2. The RMMCH delivery service also functions at different levels: 
a. It is the delivery site for all women from the surrounding geographical 
area. 
b. It is the delivery site for designated clinics in the surrounding area that 
do not have a labour ward. 
c. It is the referral centre for obstetric emergencies and obstetric “high 
risk” women from the surrounding clinics and hospitals. 
 
Therefore the population that delivers at the hospital is not the same as the 
population that booked for antenatal care at the hospital. Similarly, HIV testing 
rates and prevalence rates documented at the hospital’s antenatal clinic cannot be 
assumed to apply to the population that delivers at the hospital. The HIV testing 
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rate at the hospital’s antenatal clinic has been more than 95% over the last three 
years (personal communication, Lebogang Phakathi, PMTCT data manager, 
RMMCH). The HIV prevalence in the labour ward is unknown as it has not formed 
part of routine PMTCT reporting requirements, but will depend on the quality of 
HIV testing and counseling provided at RMMCH ANC and other centres.  
 
RMMCH has an annual number of deliveries of approximately 10 000 to 12 000 
translating into roughly 850 to 1000 deliveries per month which are accommodated 
by the following obstetric ward services: 
 
• Antenatal Ward (30 beds) with a high care unit (three beds) 
• Labour Ward Admissions Ward (ten beds) 
• Labour Ward (six stage rooms/beds) 
• Postnatal Wards 
o Normal Deliveries (22 beds – between 700-800 admissions per 
month) 
o Post-Caesarean Section Ward (20 beds – approximately 200 
admissions per month) 
• Note on stillbirths: Due to the psychological trauma associated with 
stillbirths, women whose babies are not alive at birth are admitted to the 
gynaecological wards of the hospital for postnatal care.  
• Note on women with infants born before arrival at hospital: Women who 
deliver before they reach the hospital are admitted in the same postnatal 
ward as women who deliver at the hospital. 
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The time from presenting in labour to discharge post-delivery is generally less than 
24 hours. Despite this short time it presents a window of opportunity because it is 
the one time that the vast majority of pregnant women (including those that 
delivered their infants before reaching the hospital on time) are in the hospital and 
as such a “captive population” to maximise service delivery. 
Pregnant women in labour are admitted to the labour ward admissions ward and it 
is at this point that their antenatal cards are checked by the attending staff. 
Decisions regarding provision of prophylactic ART for PMTCT are initiated here.  
 
 
1.5.3 RMMCH Postnatal Ward Population 
 
Given the diversity of the postnatal population at RMMCH, a pilot survey was done 
in the postnatal wards in 2007 to identify the major groups that make up this 
population. They were identified and are briefly described below: 
 
Women who had attended antenatal services before, came from: 
• RMMCH ANC: located on the same premises as the delivery ward. It 
serves the local area just west of the Johannesburg central business 
district. The communities are diverse in terms of socio-economic status, but 
consist predominantly of low to middle income women largely residing in 
houses.  
• Witkoppen Health Centre ANC – a government/non-governmental 
partnership site located north of Johannesburg and serving largely low 
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income women from informal settlements. The site does not have facilities 
to deliver women and hence refers all women who booked there antenataly 
to RMMCH for delivery. 
• Diepsloot ANC – a government clinic situated within the Diepsloot township 
north of Johannesburg. The township originated in the last twenty years 
and is largely an informal settlement. A high number of foreigners as well 
as refugees live in this area and it was affected by social unrest during the 
study period. There is no delivery facility and all deliveries are referred to 
RMMCH. 
• Discoverers Community Health Centre ANC – a government clinic situated 
west of Johannesburg serving a large area which includes both informal 
and formal settlements, many of which have been in existence longer than 
the Diepsloot area. The facility has a delivery ward where low-risk women 
are delivered. Any concerns or signs of risk trigger a referral to RMMCH for 
delivery. 
• Other clinics that women had booked at included various other smaller 
clinics like clinics in other provinces or even other countries as well as 
private facilities. 
 
Unbooked Women: 
• “Unbooked” women arrive for delivery without history or documentation of 
having booked for antenatal care. 
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1.5.4 PMTCT Interventions at RMMCH 
 
At each point the intervention depends on the knowledge of the health care worker 
that the woman needs the intervention i.e. the woman tells the health care worker 
her status and/or it is clearly documented (by means of the coding system) in her 
antenatal card. RMMCH offers the following services to HIV-infected pregnant 
women and their infants as recommended by the national PMTCT policy. 
 
Antenatal: 
o After diagnosis as HIV-positive, women are offered CD4 count testing and 
a bedside Haemoglobin assay. 
o CD4 Count greater than 200 x 106/litre: 
 If the Haemoglobin level is more than 8 g/dl women are given AZT 
300mg twice daily to take home when they are at 28 weeks of 
gestation or more. If the Haemoglobin level is less than 8g/dl women 
are investigated for causes of anaemia before commencing AZT. 
o CD4 Count less than 200 x 106/litre: 
 Women are fast tracked onto triple ART started at antenatal clinic 
once the woman has completed readiness counseling. 
o General counseling is done on the topics of adherence to ART (AZT or 
triple treatment), infant feeding choices of either exclusive breast or 
exclusive formula feeding and women are issued with sdNVP to be taken 
as soon as labour commences. Women are also informed about the need 
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to have their babies tested when they reach six weeks of age and that the 
baby will need to be given AZT and NVP syrup after being born. 
 
Labour and Delivery: 
o sdNVP is taken by the mother and for those who had not received the 
tablet antenataly, it is dispensed in the ward. 
o AZT 600mg is given on arrival and AZT 300mg is continued 12 hourly if 
labour is prolonged. AZT to the mother is then stopped once the infant has 
been delivered. 
 
Postnatal: 
o Infants are given sdNVP (0.6ml=6mg) syrup and commenced on AZT 
(1.2ml=12mg) syrup to be continued twice daily for either seven or 28 days 
(28 days if the mother received less than four weeks of antenatal ART 
prophylaxis). 
o Infant feeding choice is rediscussed and mothers electing to exclusively 
formula feed are issued with their first tins of NAN Pelargon milk. 
o All HIV-exposed infants are referred for HIV PCR testing at six weeks of 
age which is preceded by a registration and information visit when the baby 
is two weeks old. Women who had initially booked at clinics other than the 
RMMCH antenatal clinic are referred back to those clinics for HIV PCR 
testing. 
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Infant Visits: 
o Two week registration, counseling and information session. 
o Six week infant test, all infants started on cotrimoxazole prophylaxis. 
o Ten week return for test results, cotrimoxazole stopped if infant is HIV-
negative and not being breastfed. 
o Breastfed infants are kept in follow-up and on cotrimoxazole and retested 
(if initially HIV-negative) six weeks after the cessation of breastfeeding. 
o All HIV-infected infants are immediately referred into the HIV follow-up 
clinic at the same location where their care is continued. 
 
Since the program’s inception, there has been an emphasis on routine and early 
infant follow-up for HIV-exposed infants with provision of cotrimoxazole 
prophylaxis for all HIV-exposed infants until they could be proven to be uninfected. 
Routine infant HIV PCR testing was introduced in 2004 at the age of six weeks. 
The “source” of these routinely tested HIV-exposed infants has largely consisted of 
those infants born to women who were diagnosed as HIV-positive during their 
antenatal clinic attendance at RMMCH or other local clinics.  It follows that infants 
born to mothers tested at antenatal clinics with high testing rates had the best 
chance to be identified at delivery, benefiting from both maternal and infant ARV 
prophylaxis and then being referred on for PCR testing. Babies born to women 
who did not know their HIV status at the time of delivery were unlikely to receive 
any ARV prophylaxis or be referred since there was no protocol in place for this.  
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Since 2005, all infant tests done routinely (i.e. at six weeks of age in babies known 
to be exposed) have been captured on an electronic database to facilitate 
statistics reporting. All HIV-infected infants are referred to the HIV treatment clinic 
for monitoring and initiation of antiretroviral therapy when indicated. This flow of 
patients has made it possible to present information on clinical progression and 
need for ART in HIV-infected infants [35, 36]. The rate of HIV transmission to 
infants born to HIV-infected women has been demonstrated to be under 10% in 
this largely formula fed population [32, 33, 34]. 
The program requires that infants born at RMMCH, but originating from antenatal 
clinics further afield be tested at those clinics rather than at RMMCH. Outreach 
and training provided the necessary skills and since 2006 a process of “down-
referral” for infant testing ensued which has led to a reduction in the routine infant 
testing at RMMCH. Since then and with the advent of AZT provision in March 
2008, there has been a growing emphasis on maternal testing rates at the 
antenatal and delivery services to ensure that there were no missed opportunities 
in terms of enrolling pregnant women into the PMTCT program.  
 
 
1.5.5 Monitoring and Evaluation of PMTCT 
 
The five main indicators used by the South African DOH to report on the quality of 
PMTCT before the introduction of AZT to the protocol are described below. The 
process of establishing new indicators and reporting tools to accommodate the 
addition of AZT is still in progress. The indicators are described to show the 
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reporting framework and to point out that the concept of “HIV testing uptake” and 
“HIV prevalence” in women is very much the focus of only the antenatal indicators 
(1-3). The labour ward and infant testing indicators (4 and 5) rely very heavily on 
HIV testing antenataly as well as on accurate communication of results (on the 
antenatal card) to the delivery and postnatal staff. The coding system of HIV 
results on the antenatal card is another systematic issue that has to work properly 
before the communication of the woman’s HIV status at the time of labour is 
possible, if the woman does not voice it herself. Only with this chain intact do the 
indicators show meaningful results.  
1) HIV testing rate in new antenatal women (new=first visit) 
a) Numerator: New ANC attendees tested for HIV 
b) Denominator: All new ANC attendees 
2) HIV positivity rate amongst antenatal women 
a) Numerator: New ANC attendees tested HIV-positive 
b) Denominator: New ANC attendees tested for HIV (1a) 
3) Nevirapine uptake rate in women (dispensing at ANC) 
a) Numerator: number of ANC attendees given sdNVP to take home 
b) Denominator: New ANC attendees tested HIV-positive (2a) 
4) Nevirapine uptake rate in babies 
a) Numerator: Nevirapine doses given to babies 
b) Denominator: Babies born to HIV-positive women 
5) HIV positivity rate in babies 
a) Numerator: infants with positive PCR Results 
b) Denominator: Infants PCR tested  
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It is apparent that the first three indicators are more closely related to each other 
than the last two. Looking at the indicators listed above (specifically the 
denominator of the fourth indicator), one can see that this indicator only reflects 
reality if the number “infants born to HIV-positive mothers” is a true reflection of the 
number of HIV-positive women who delivered. With the introduction of AZT the 
indicators containing “Nevirapine” will be adjusted to include “dual-” or “multi-
therapy” PMTCT. There is an inherent assumption that women know their status 
when they arrive for delivery or, that they will automatically be tested if they do not 
know their status. The following questions arise: How accurate is the reported 
number “Infants born to HIV-positive women” at RMMCH? How big is the gap 
between the total delivering population and the population of women who know 
their HIV status? Can routine testing around delivery improve this gap if it exists 
and improve access of infants to both prophylactic ART as well as infant testing? 
Monitoring and evaluation of the PMTCT program is crucial to improve service 
delivery and facilitate financial planning locally and at higher levels. The purpose 
of operational research around PMTCT at RMMCH is aimed at finding effective, 
affordable and reproducible interventions that prevent HIV infection and improve 
access to care in terms of the NSP 2007-2011. 
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Chapter 2 - Study Objectives and Hypothesis 
 
2.1 Objectives 
 
A. To assess the impact of a routine peri-partum maternal HIV testing service 
in the ante- and postnatal wards at RMMCH on the PMTCT program as 
measured by:  
1. An increase in number of women identified as being HIV-infected as a 
result of peri-partum HIV testing 
o Assess the ANC/pre-delivery HIV Testing dynamics for the 
whole and for each of the major groups that make up the 
RMMCH delivery population 
 Percentage of women knowing their HIV status on arrival 
for delivery 
 Percentage of women with improved knowledge of their 
HIV status (either changed status or found out their 
status for the first time) on leaving the facility post-
delivery 
o Assess the reliability of verbal and documented HIV-negative 
status for women retested 
2. An increase in number of women and infants accessing prophylactic 
PMTCT medication around the time of delivery 
3. An increase in infants accessing early routine HIV testing 
4. The rate of transmission of HIV to the HIV-exposed infants identified 
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5. An increase in HIV-infected infants accessing HIV-related care 
o Access to prophylaxis against opportunistic infections 
o Access to the paediatric comprehensive HIV care, management 
and treatment (CCMT) service at RMMCH 
 
B. To estimate the effect of a routine peri-partum testing service on the 
accuracy of the standard reported infant PMTCT uptake indicator. 
 
 
2.2 Primary Null Hypothesis 
 
Routine peri-partum HIV testing and counseling of women in the ante- and 
postnatal wards does not improve access to HIV prevention, testing and treatment 
for their infants. 
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Chapter 3 – Methods 
 
3.1 Patient Selection and Sample Size 
 
The study assessed an intervention at an operational level in the delivery and 
post-delivery service at RMMCH. A convenience sample of 2500 women, half of 
the population of women expected to deliver at RMMCH over the six-month study 
period, was chosen. Two full-time counsellors interviewed the women and 
obtained written informed consent for the study. Enrolment was conducted seven 
days a week between 07h00 and 16h00 on weekdays and 08h00 and 12h00 on 
weekends. Women discharged from the postnatal service on weekend afternoons 
or after 16h00 during week day afternoons were thus not enrolled in the study. On 
busy days an additional counsellor, usually stationed in the antenatal clinic, 
assisted the study counsellors to ensure that as many women delivering at the 
facility as possible were captured.  
 
The counsellors did regular daily ward rounds in all obstetric wards, including the 
post-Caesarean section ward and the ward where mothers were admitted 
following normal vaginal deliveries. They interviewed all women with live births. 
The counsellors aimed to include all women on their register (Appendix A) which 
was an existing tool before the start of the study and part of the monitoring routine 
in the hospital aimed at assisting the nursing staff to capture accurate routine 
statistics and ensure identification of HIV-infected women. While entering the 
women on the register the counsellors had to ask questions regarding their HIV 
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status, booking site as well as postnatal plans. At this point women were invited to 
join the study and written informed consent (Appendix B) was obtained for those 
that agreed. 
 
Eligibility Criteria: 
1. Any woman arriving at the hospital in labour 
2. Any mother in the postnatal ward having delivered a live baby.  
3. Enrolment in the study occurred irrespective of the maternal HIV status (i.e. 
HIV-positive, HIV-negative or unknown) and the mother’s willingness to 
undergo an HIV test. 
 
Exclusion Criteria: 
1. Women under the age of 18 years at the time of interview 
2.   Any women presenting without a live birth (e.g. miscarriage, stillbirth or 
voluntary termination of pregnancy). 
 
Rapid HIV testing as per the national DOH protocol was considered necessary 
and offered if  
• the woman’s HIV status was unknown, 
• there was a discrepancy between the HIV-status verbally reported by the 
woman and the status documented on the patient held antenatal card, 
• the woman reported her status but no status was documented, 
• the woman reported or had a documented HIV-negative status which was 
established more than six weeks ago. 
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If the offer of an HIV test was accepted, written informed consent for the test was 
obtained (Appendix B). Results were made available prior to discharge from the 
ward and generally within 45 minutes of venesection. Appropriate counseling and 
PMTCT related interventions were provided and efforts were made to ensure 
privacy and confidentiality by doing the counseling in a separate room. After the 
diagnosis was given, each newly diagnosed HIV-positive woman was counseled 
and given emotional support as well as an appointment for her next visit. Although 
rapid HIV tests were used, these were not performed at the bed side. There were 
usually five to fifteen samples to process daily and it was more practical to 
venesect all women and perform the rapid tests in a batch. These samples were 
processed by the trained laboratory technician or if not available (e.g. weekends or 
public holidays) by trained counselors supervised by nursing staff or the attending 
doctor in a dedicated side room located in the paediatric HIV clinic. 
 
Women who were either known to be HIV-positive or who were newly diagnosed 
as positive following the above-mentioned testing protocol received the PMTCT 
interventions according to standard protocol at RMMCH. 
 
A CD4 Count test was submitted for women newly diagnosed as HIV-positive with 
a return date for results two weeks later to coincide with the date of infant 
registration visit before testing. Since women who were diagnosed HIV-positive 
antenataly generally had CD4 count results and had their CD4 counts routinely 
repeated at the two week infant registration visit, their CD4 counts were not done 
at the time of delivery. The intended feeding choice as well as the intended infant 
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follow-up site was documented (Appendix A). HIV testing of partners and other 
children was offered to all HIV-positive women. If women brought their infants 
back to RMMCH for PCR testing, results were obtained directly from the laboratory 
as part of the clinic service. For all infants who did not return and may have been 
tested elsewhere, the National Health and Laboratory Service (NHLS) database 
was searched using infant surname and date of birth as identifiers to improve the 
quality of data and minimise the effect of loss to follow-up.   
 
 
3.2 Explanation of Study Terms: 
 
• Arrival status: This refers to the HIV status reported/stated by a woman 
when first interviewed in the delivery and/or post-delivery setting. This is 
also referred to as the “verbal status” in the results section. In terms of 
treating or preventing HIV the status reported verbally and therefore 
assumed to be “known” by individual women is conceptually important as it 
lays the foundation for women to acknowledge the need for and accept any 
treatment. 
 
• Documented status: This is the HIV status that was found documented in 
the antenatal clinic card carried by the woman. The decision whether or not 
a woman was offered an HIV test or a retest depended on both verbal and 
documented status but in cases of uncertainty the documented status took 
precedence, i.e. if a woman said (verbal status) that she was tested HIV-
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negative less than six weeks ago, but her antenatal card (documented 
status) showed that her HIV-negative result came from a test done more 
than six weeks ago, she would be offered a test. Similarly all women with 
discrepant verbal and documented status or with no documented status 
were offered a retest. 
• Departure status: This refers to the HIV status newly established or already 
known to the woman by the time she was discharged post-delivery and had 
thus had the opportunity to go through the testing or retesting process that 
was offered.  
 
An analysis was done for all women who reported an HIV-negative status and 
went on to have an HIV test to assess the negative predictive value (NPV) of a 
verbally reported HIV-negative status compared to a documented HIV-negative 
status.  
 
 
3.3 Rapid HIV Tests 
 
The standard HIV testing algorithm according to the DOH PMTCT policy [10] is 
represented below: 
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Figure 3.1: South African DOH Rapid HIV Testing Algorithm 
  
The test kits on government tender during the study period were the SD Bio-line 
HIV-1/2 Version 3.0 (Standard Diagnostics Inc., Hagal-dong, Korea) as the 
screening test and the Acon HIV 1/2/0 Tri-line Rapid Test Device (Acon 
Laboratories, Inc., San Diego, USA) as the confirmatory test. During the study 
period counsellors and nurses involved with antenatal care raised concerns about 
these tests yielding false positive results and preferred using the 4th generation 
HIV Ag/Ab ELISA (Abbott Laboratories, Wiesbaden, Germany) tests done by the 
NHLS. To establish the validity of these concerns, 400 DetermineTM HIV-1/2 
(Abbott Laboratories, Illinois, USA) were purchased and run concurrently with 400 
antenatal standard protocol HIV tests. Accuracy of the individual kits and the DOH 
Rapid HIV test algorithm was determined by comparing the results with an HIV 
ELISA test for the first 200 tests run. Subsequently, 200 samples were run 
SCREENING HIV TEST 
Finger prick test or drop from specimen 
tube 
SCREENING RESULT POSITIVE SCREENING RESULT NEGATIVE = 
FINAL NEGATIVE RESULT 
CONFIRMATORY HIV TEST 
Finger prick test 
CONFIRMATORY RESULT POSITIVE 
= FINAL POSITIVE RESULT 
 
CONFIRMATORY RESULT NEGATIVE 
 INDETERMINATE OUTCOME  DO 
ELISA 
RETEST AT 34 WEEKS 
INDETERMINATE ELISA: BLOOD 
SENT FOR p24 Ag OR DNA PCR 
TEST 
POSITIVE / NEGATIVE ELISA  
FINAL RESULT 
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checking all HIV-positive results with an HIV ELISA test. The DOH protocol 
includes an HIV ELISA test only if there is a discrepancy between the two rapid 
test results. The Determine kit has been available since 1989 and is considered a 
well validated, highly sensitive and specific rapid HIV test including in viral 
subtypes prevalent in Africa [37]. It is not routinely used in South Africa because it 
is not on state tender but it was used in this instance to provide an alternative if 
other tests performed poorly in the validation process. 
 
 
3.4 Patient Consent and Ethical Considerations 
 
Consent for HIV testing outside of the study was routinely sought in writing as per 
standard practise (Appendix C) and women had the choice to refuse an HIV test. 
Informed consent for involvement in this study was sought with consent for an HIV 
test where necessary at the same time (Appendix B). All patient information was 
kept confidential as per standard practise. A submission was made to the ethics 
committee of the University of the Witwatersrand to report on the study findings as 
well as to enrol patients in the study and this was unconditionally approved on the 
4th of April 2008 (Protocol number M080203 – Appendix D). 
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3.5 Statistical Methods and Analysis 
 
Results were captured on the register (Appendix A) and the information was 
entered into a Microsoft Access 2003 database. Data was checked prior to and 
following entry into the electronic database. For the purposes of confidentiality of 
the study group, a separate database was extracted from the main database 
which did not contain any patient identification other than a study number and this 
was only available to the principal investigator. All consent forms and paper 
registers (Appendix A) containing routinely collected data were locked away. Only 
the principal investigator knew which women were part of the study when women 
returned for infant testing. Data gathered from the Microsoft Access database 
were analysed using Microsoft Excel spreadsheets as well as SAS version 9.1 
(2002-2003 by SAS Institute Inc., Cary, NC, USA). Basic descriptive statistical 
methods where used in the analysis of the data. Statistical comparisons were 
performed using the Chi-square test for categorical variables and for non-
parametric data with small numbers the Fisher Exact test was used.  
 
3.6 Measurable Outcomes 
 
Pregnant Women and Mothers: 
From the routinely completed ward register (Appendix A): 
I. Total number of women interviewed 
II. Total number of women enrolled in the study 
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Women from the latter group were then stratified into the following groups  
1. Women with positive HIV status 
2. Women with unknown HIV status who either 
a. Refused an HIV test or 
b. Tested HIV-positive or  
c. Tested HIV-negative 
3. Women with negative HIV status (stratified further into reported versus 
documented and into those tested less than six weeks ago, six to twelve 
weeks ago or more than twelve weeks ago) who either 
a. Refused an HIV test or 
b. Tested HIV-positive or  
c. Tested HIV-negative 
 
All women were stratified according to their original booking site, and per booking 
site women were stratified according to points 1) and 2) above 
 
HIV-exposed Infants: 
Outcomes were stratified according to: two groups of infants: 
1. Infants born to women with a known HIV-positive status at the time of 
delivery because PMTCT services had been accessed antenataly. 
2. Infants born to women whose HIV-positive status was first established in 
the peri-partum period as a result of this study and who then accessed 
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PMTCT services around the time of delivery. This group also included 
infants born to women who had initially tested HIV-negative during 
antenatal care. 
 
These two groups were then compared with regard to their  
1. Total numbers 
2. Type of PMTCT drug intervention accessed 
3. Rates of return for early infant testing at six weeks of age and concurrent 
initiation of cotrimoxazole prophylaxis 
4. Vertical transmission rates at six weeks of age  
5. Rates of access to the RMMCH CCMT service for antiretroviral therapy for 
infants diagnosed as HIV-infected. 
 
 
3.7 Expected Beneficial Outcomes not Directly Measured 
 
An increased number of women would be more knowledgeable about HIV and 
their own HIV status. If they tested negative they would potentially benefit by 
maintaining a negative HIV status. If they tested HIV-positive they would benefit by 
accessing care for themselves and their families. HIV-positive women would be 
able to prevent future pregnancies or plan them more carefully taking into 
consideration risks to themselves and a future child. These benefits would address 
both the first two prongs of the WHO PMTCT approach, albeit for future 
pregnancies in these individuals. There could also be a benefit in terms of general 
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increased knowledge and awareness about HIV infection and its consequences 
and available treatments which could lead to greater compliance later with HIV 
care. 
 
 
3.8 Funding 
 
Funding for the counsellors and data-capturers was secured through a PEPfAR 
(President’s Emergency Plan for AIDS Relief, USA) grant through the US Centers 
for Disease Control and Prevention directed at work promoting identification of 
HIV-infected infants early in life. The HIV preventative and treatment related 
service delivery of the RMMCH Empilweni HIV Clinic was supported by the 
University of the Witwatersrand Paediatric HIV Clinics, also known as ECHO 
(Enhancing Children’s HIV Outcomes). Computers and software at RMMCH were 
used to capture and analyse results. 
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Chapter 4 – Results 
 
4.1 Source of Study Population – Women 18 Years or Older 
 
Figure 4.1: Overview of Study Population. The women interviewed were a subset of the women 
with live births during the study period and enrolled women formed a subset of the women 
interviewed with those under the age of 18 years being excluded.  
 
During the study period of 167 days (five and a half months between the 9th of 
April and the 23rd September 2008), 3684 (71.3%) women out of 5169 women with 
live births were interviewed around the time of delivery in the RMMCH obstetric 
wards. Of the 3684 women interviewed, 2419 (65.7%) were enrolled in the study. 
This means that during the study period 46.8% of all women with live births were 
enrolled, slightly less than the 50% convenience sample aimed for in the study 
Women with Live 
Births (n=5169) 
Women Interviewed 
(n=3684)  
Women Enrolled in 
Study (n=2419)  
Women 18 years of 
age or older (n=3525)  
Women under 18 
years of age (n=159)  
Women Refused 
Enrolment (n=1106)  
Women Reporting 
HIV-negative status 
(n=1650)  
Women Reporting 
HIV-positive status 
(n=490)  
Women Reporting 
Unknown HIV status 
(n=279)  
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design. The study aimed to enrol half the women presenting for delivery, but the 
counsellors’ working hours, consent refusal and the fact that about 5% of women 
delivering were under 18 years old meant that only 46.8% of the total delivering 
population was enrolled.  
 
Figures 4.2 and 4.3 highlight the diversity of the enrolled population in terms of 
antenatal booking history. 
 
 
Women Making Up RMMCH Delivery Population 
24%
10%
6%
7%
24%
29%
RMMCH ANC
Witkoppen ANC
Diepsloot ANC
Discoverers ANC
Other ANC
Unbooked
 
Figure 4.2: Booking History of Enrolled Women (n=2419) 
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Women Making up "Other ANC" Group
2%
35%
18%
2%
9%
1%
2%
31%
Other Hospitals in
Gauteng
Ekurhuleni and Tshwane
Clinics
Westrand and Soweto
Clinics
City of Johannesburg
Clinics (excl Soweto)
Other Province
Other Country
Private Sector
Other/Unknown
 
Figure 4.3: Geographical Distribution of Antenatal Bookings in the “Other ANC” Group 
(n=568). A large percentage (24% in Figure 4.2) of the enrolled population received antenatal care 
outside the RMMCH catchment area with more than 57% booking at antenatal clinics in Gauteng 
province. The “Other/Unknown” group in this figure were women who had evidence of having 
received antenatal care, albeit that the clinic name had not been captured by the counsellors.  
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4.2 Study Progress and Representativity of the Study Sample 
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Figure 4.4: Progress of Study Recruitment Over Time. The study enrolment pattern changed 
over time as progressively higher percentages of interviewed women were enrolled [   ]. In the first 
three months 36% of the study sample was enrolled. 
 
Although two thirds of the study sample was enrolled in the second three months 
of the study creating the potential for bias, the study results did not change over 
time.  
 
Baseline variables routinely collected at RMMCH for the interviewed population 
were compared to the enrolled population to determine whether statistically 
significant differences were evident (Table 4.1). The median age of all women 
interviewed excluding those that were under 18 years of age (n=3525) was 25.94 
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years and the median age of the enrolled group was 25.85 years. Both groups had 
the same inter-quartile range of 22.5 to 30.6 years and no statistically significant 
difference was found (p=0.70) between the two groups. No other baseline 
variables (e.g. parity) were available for comparison. 
 
Contribution by each 
subgroup 
Interviewed 
(n=3684) 
Enrolled 
(n=2419) 
p-value 
(Chi-square) 
RMMCH ANC 900 (24.4%) 577 (23.9%) 0.61 
Witkoppen ANC 1060 (28.8%) 710 (29.4%) 0.63 
Diepsloot ANC 373 (10.1%) 238 (9.8%) 0.72 
Discoverers ANC 232 (6.3%) 150 (6.2%) 0.88 
Other ANC 857 (23.3%) 568 (23.5%) 0.84 
Unbooked 262 (7.1%) 176 (7.3%) 0.81 
Women knowing their 
HIV status on arrival for 
delivery 
3246 (88.1%) 2140 (88.5%) 0.67 
 
Table 4.1: Comparison of Interviewed and Enrolled Women Delivering at RMMCH. No 
significant differences were noted in the distribution of antenatal booking history or knowledge of 
HIV-status on arrival between interviewed and enrolled population of women. 
 
The convenience sample of 2419 enrolled women comprising 46.8% of all live 
births during the study period was representative of the 3684 interviewed women 
who comprised 71.3% of all women with live births during the study period. Bias in 
remaining 28.7% of women cannot be excluded however it was unlikely on 
grounds that the women that were not interviewed were different only in terms of 
being discharged during weekend afternoons or late weekday afternoons. The 
study outcomes therefore apply to at least 71% of all women delivering live births 
at RMMCH. 
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4.3 Accuracy of HIV Rapid Tests and Algorithm 
 
HIV ELISA results on samples from 200 pregnant women were used as the 
standard against which the performance of individual rapid test kits and the DOH 
testing algorithm were measured (Table 4.2).  
 
 
 
HIV Status  
(HIV ELISA result) Statistical Indicators 
 
 Positive Negative Sens Spec PPV NPV 
SD Bio-line 
HIV-1/2 
Version 3.0 
Positive 27 0 
100% 100% 100% 100% 
Negative 0 173 
Acon HIV 
1/2/0 Tri-line 
Rapid Test 
Device 
Positive 27 2 
100% 98.8% 93.1% 100% 
Negative 0 171 
DetermineTM 
HIV-1/2 
Positive 27 0 
100% 100% 100% 100% 
Negative 0 173 
DOH Serial 
Rapid 
Algorithm 
Positive 27 0 
100% 100% 100% 100% 
Negative 0 173 
 
Table 4.2: Accuracy of Rapid Kits and Serial DOH Algorithm. No false positive or false 
negative results were noted when the routine rapid test algorithm was used despite the Acon HIV 
1/2/0 Tri-line test yielding two false positive results. “Sens” = sensitivity, “spec” = specificity, “PPV” 
and “NPV” = positive and negative predictive value respectively. 
 
The subsequent 200 women tested demonstrated 100% specificity with the DOH 
algorithm using the HIV ELISA result as the standard and 100% sensitivity and 
specificity in comparison to the DetermineTM test. Although the serial DoH 
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algorithm was 100% sensitive and specific, the false positive results for the 
confirmatory test (Acon) are worrying in that these highlight a potential for falsely 
diagnosing women as HIV-infected if the protocol is not correctly adhered to.  
 
 
4.4 Enrolled Population and Study Objectives 
 
4.4.1 Identification of Additional HIV-positive Women 
 
HIV Status Reported by Women on Arrival for Delivery 
 
The HIV status reported in the initial interview was a positive status in 490 
(20.3%), a negative status in 1650 (68.2%) and an unknown status in 279 (11.5%) 
women (Figures 4.1 and 4.5).  
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Reported HIV-status on Arrival
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Figure 4.5: Reported HIV Status on Arrival. Knowledge of HIV status and HIV prevalence differs 
between groups of women from different antenatal sites.  
 
A high percentage of women who booked at RMMCH, Witkoppen and Discoverers 
ANC reported knowing their HIV status in comparison to women booking at 
Diepsloot and other ANC’s. Where women had not received antenatal care, there 
was both a strikingly low knowledge of their HIV status and high HIV prevalence. 
The heterogeneity with respect to knowledge of HIV status and HIV prevalence of 
the delivering population at the regional delivery site (RMMCH) in comparison to 
the antenatal clinic at RMMCH is highlighted. 
 
Percentage 
Absolute Number 
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Women Reporting an HIV-negative Status 
 
Women reporting an HIV-negative status were offered a retest if they reported an 
HIV-negative status established more than six weeks prior to enrolment (Table 
4.3).  
 
 
Total 
reported 
HIV-
negative 
Total offered 
retest 
Retest 
Refused 
Retest 
positive  
All Women in group 1650 815 (49.4%) 47 (5.8%) 32 (4.2%) 
Negative 6-12 weeks 
ago 815 
402 (49.3%) 22 (5.5%) 17 (4.5%) 
Negative >12 weeks 
ago 413 (50.7%) 25 (6.1%) 15 (3.9%) 
RMMCH ANC 469 130 (27.7%) 8 (6.2%) 1 (0.8%) 
Witkoppen ANC 496 281 (56.7%) 13 (4.6%) 2 (0.7%) 
Diepsloot ANC 164 76 (46.3%) 7 (9.2%) 10 (14.5%) 
Discoverers ANC 109 63 (57.8%) 5 (7.9%) 1 (1.7%) 
Other ANC 406 260 (64.0%) 14 (5.4%) 18 (7.3%) 
Unbooked 6 5 (83.3%) 0 (0%) 0 (0%) 
 
Table 4.3: Test Acceptance and HIV Prevalence in Women Reporting an HIV-negative Status. 
The difference between refusal and positive testing rate in women reporting a negative result six to 
twelve weeks ago versus women reporting a negative result more than 12 weeks ago was not 
statistically significantly different on a chi-square test (p=0.72 and 0.67 respectively). 
 
In total, 835 (50.6%) of 1650 women who reported an HIV-negative status had 
been tested within the preceding six weeks. Using the cut-off of having had an HIV 
test more than six weeks ago as a criterion for offering a retest revealed that 32 
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(4.2%) of this group had either seroconverted in late pregnancy or had reported 
their HIV status incorrectly. The highest rates of “seroconversion” were seen in the 
Diepsloot and “Other ANC” groups, the same two groups that had slightly lower 
knowledge of HIV status amongst ANC attendees (Figure 4.5).  
These mother-infant pairs would have been missed had they not been offered a 
retest.  
 
 
Women Reporting an Unknown HIV Status 
 
All 279 women in this group were offered a test but 33 (11.8%) refused. Of the 246 
(88.2%) who consented, 69 (28.0%) tested positive (Table 4.4). 
 
 
Total 
(n=279) 
Refused Test 
(n=33) 
 Test positive 
(n=69) 
RMMCH ANC 6 0 (0%) 2 (33.3%) 
Witkoppen ANC 13 2 (15.4%) 5 (45.5%)  
Diepsloot ANC 24 2 (8.3%) 7 (31.8%) 
Discoverers ANC 1 0 (0%) 1 (100%) 
Other ANC 71 12 (16.9%) 10 (16.9%) 
Unbooked 164 17 (10.4%) 44 (29.9%) 
 
Table 4.4: Test Acceptance and Prevalence in Women Reporting an Unknown HIV Status. 
The percentage of women who refused a test has the total number as a denominator while the 
percentage of women who had a positive result has the number of women agreeing to a test as its 
denominator. 
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Although the numbers were small in women with unknown HIV status on arrival 
the HIV prevalence amongst those tested in this group approximated the 
prevalence figure for Gauteng (30.3%) from the 2007 anonymous survey [2].  
 
 
Women reporting an HIV-positive status  
 
Only seven (1.4%) of 490 women reporting an HIV-positive status were offered a 
retest because no supporting documentation of their status was evident on their 
antenatal records. All seven women were confirmed to be HIV-positive. 
 
 
Reliability of a Reported HIV-negative Status 
 
To establish the reliability of a verbally reported HIV-negative status on arrival, the 
retesting results were stratified according to whether the women had 
documentation of their status or not (Table 4.5).  
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Documented HIV 
Status 
Total 
(n=1650 reported 
HIV-negative) 
Refused 
Test 
Retest 
Positive 
NPV of reported 
Status 
HIV-Positive 7 (0.4%) 0 (0%) 6 (85.7%) 14.3% 
No Documentation 64 (3.9%) 4 (6.3%) 9 (15.0%) 85.0% 
HIV-negative 1579 (95.7%) 43/744 (5.8%) 17 (2.4%) 97.6% 
 
Table 4.5: Reliability of Reported HIV-negative Status. The 835 women not retested had 
documentation of a recent HIV-negative result (less than six weeks before).  
 
 Of all women who enrolled in the study there was one who was falsely diagnosed 
as HIV-positive according to her documented antenatal result. Women who 
reported a negative result when their antenatal card showed a positive result were 
more likely to be HIV-positive than women with no documentation or with a 
documented HIV-negative status as demonstrated by the increasing NPV. With a 
verbally reported HIV-negative status, women without documentation had a higher 
chance of being infected (p<0.001). 
 
 
Change in Knowledge of HIV Status between Arrival to and Departure from 
RMMCH 
 
The reported HIV status was compared to the departure status for all women after 
counseling and testing had been completed for those that qualified (Figure 4.6).  
 - 45 -
Change in Knowledge of Status and HIV 
prevalence from Arrival To Departure (%)
10.2
1 1.5
9.2
0.7
10.4
-18.6
83.5
3.11.250.50.31.9
-25
-20
-15
-10
-5
0
5
10
15
20
25
To
ta
l
RM
M
CH
 
W
itk
op
pe
n
Di
ep
slo
ot
Di
sc
ov
er
er
s
Ot
he
r A
NC
Un
bo
ok
ed
Knowledge of Status
HIV Prevalence
 
Figure 4.6: Change in HIV Prevalence and % Knowledge of HIV status. An increase in the level 
of knowledge of HIV status was seen in all groups but was highest in the unbooked group due to 
the high number of women of unknown status. The HIV prevalence increased in all groups except 
for the “Unbooked” group where it decreased from 50% to 31.4% as the number of tested women 
in this group increased from 12 to 159 women. 
 
The difference in the number of women reporting a known HIV status on arrival 
versus those with a known HIV status on departure was 246 (10.2%) out of the 
total group of 2419 (Figure 4.6) with 33 (1.4%) of 2419 women leaving the 
postnatal service without a known HIV status. In addition 32 women who reported 
an HIV-negative status were shown to be HIV-positive after being retested. 
Therefore the number of women with improved knowledge of their status was 
actually 278 (11.5%) of 2419. They comprised 177 women with previously 
unknown HIV status that were newly identified as HIV-negative and 101 women 
newly diagnosed as HIV-positive comprising 7.3% and 4.2% of the enrolled 
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population respectively. The number of HIV-positive women identified increased 
by one fifth (20.6%) for the whole group (Table 4.6). 
 
 
Whole 
Group RMMCH  Witkoppen Diepsloot Discoverers 
Other 
ANC Unbooked 
A: Total 
Women 2419 577 710 238 150 568 176 
B: Known HIV-
positive on 
arrival 
490 102 201 50 40 91 6 
C: Newly 
diagnosed 
HIV-positive 
women 
101  3 7 17 2 28 44 
C as % of A 4.2 0.5 1.0 7.1 1.3 4.9 23.5 
C as % of B 20.6 2.9 3.5 34.0 5.0 30.8 733 
 
Table 4.6: Additional HIV-positive Women Identified.  More than 4% of the total population were 
newly identified as HIV-positive originating predominantly from “Diepsloot”, “Other ANC” and 
“Unbooked” subgroups.  
 
Although only 872 (36%) of the total 2419 women (Figure 4.4) were enrolled in the 
first three months of the study, 39 (4.5%) were newly diagnosed as HIV-positive 
which is comparable to 101 (4.2%) of all 2419 women (Chi-square p-value=0.72). 
Identifying 101 additional HIV-positive women from the time of arrival for delivery 
to the time of departure represented a statistically significant increase in the 
number of infected women and therefore HIV-exposed infants identified (Chi-
square p<0.001). Extrapolated over a one year period at RMMCH where there are 
10 000 to 12 000 deliveries per annum there would be about 420 to 504 newly 
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diagnosed HIV-positive women amounting to 35 to 42 per month. Even if the study 
population was representative of only 71% of the women delivering live births, i.e. 
those interviewed during the study period, at least 25 to 30 additional HIV-positive 
women would be identified per month.  
 
 
4.4.2 Increased Access to PMTCT Interventions 
 
The process of interviewing and testing occurred largely in the postnatal as 
opposed to the labour ward since this was more practical and acceptable to the 
women. Counseling women for an HIV test at the time of the first stage of labour 
was not impossible but far less practical than after the delivery. Most women 
presented in the active rather than latent phase of the first stage and only eight of 
the 101 newly diagnosed women were tested pre-delivery. Those women who 
knew their HIV-positive status at arrival for delivery had usually (94.9% of cases) 
received PMTCT-related interventions like ART prophylaxis (Table 4.7) and 
counseling during their antenatal care. The 101 newly identified HIV-positive 
women were offered sdNVP and AZT syrup for their infants as well as infant 
feeding counseling. Of the eight women newly identified in the labour ward as 
being HIV-positive, six received sdNVP only and two received sdNVP and AZT 
(single) doses prior to the birth of their infants. The reason for the six women not 
receiving AZT was as a result of national guidelines recommending that women 
presenting in labour without having received AZT should receive only sdNVP. The 
two women who received single dose AZT should theoretically not have received 
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this. No multiple births were recorded in the enrolled women who were known or 
newly diagnosed HIV-positive. 
 
The benefit of the study in providing additional PMTCT medications was inherently 
linked to the first objective of identifying more HIV-exposed women. This benefit 
could only be guaranteed for the doses administered by or under observation of 
the nursing staff. Once discharged from the hospital, the onus was on the mother 
to continue administering the AZT syrup. It was assumed that the support and 
counseling provided around the time of testing would have helped to encourage 
mothers to comply with treatment. This was not the case for at least two women 
where the reaction to the diagnosis resulted in refusal to comply with further 
PMTCT follow-up. 
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HIV-positive Mothers and Exposed Infants 
 Known before 
delivery 
Newly diagnosed 
perinataly 
Total mother child pairs 490 101 
PMTCT Drug interventions   
sdNVP and AZT to both 
a) mom > 4wks, baby 1 wk 120 (24.5%) 0 (0%) 
b) mom < 4wks, baby 4 wks 189 (38.6%) 2 (2.0%) 
HAART to mother and NVP, 
AZT to baby 83 (16.9%) 0 (0%) 
NVP to both and 4-weeks 
AZT to baby 73 (14.9%) 6 (5.9%) 
NVP and 4-weeks AZT to 
baby only 25 (5.1%) 91 (90.1%) 
No prophylaxis 0 (0%) 2 (2.0%) 
Infant Feeding Intention   
Exclusive breast-feeding 17 (3.5%) 6 (6.1%) of 98 
Infant Follow-up Intention   
Infant follow-up at RMMCH 203 (41.4%) 83 (83.8%) of 99 
 
Table 4.7: PMTCT Interventions in Known versus Newly Diagnosed HIV-positive Women. All 
the infants born to newly diagnosed HIV-positive women would not have received PMTCT-related 
interventions if the woman had not tested at the time of delivery. There were two mothers who 
refused to continue administering the prophylactic medications at home or to bring their infants for 
testing and these two and an additional mother refused to agree to exclusive feeding (breast or 
formula).  
 
Of the women already known to be HIV-positive at the time of arrival for delivery, 
more than 60% had had some AZT and a quarter had received AZT for longer 
than four weeks by the time of delivery. Together with the 16.9% of women who 
were on triple therapy a total of 80% of women hailing from all antenatal clinics 
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had received PMTCT interventions according to the current PMTCT protocol. On 
the other hand 20% of all women previously diagnosed as HIV-positive had 
received no antenatal ART except sdNVP in 14.9%. 
 
Exclusive formula feeding was the most commonly chosen infant feeding option by 
HIV-positive mothers. Women who were newly diagnosed as HIV-positive were 
requested to return to RMMCH for infant PCR testing and to receive their own 
CD4 count results from the sample submitted at diagnosis. More than 80% of 
these women reported an intention to return to RMMCH (Table 4.7).  
 
 
4.4.3 Infant Follow-Up Dynamics 
 
The cascade of events in following up HIV-exposed infants from the time of 
delivery is depicted in Figure 4.7. 
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Figure 4.7: Cascade of Follow-up for Known and Newly Diagnosed HIV-exposed Infants. 
After two mothers in the newly diagnosed group did not agree to continue follow-up the largest 
subsequent drop-off occurred with infant testing. As far as could be ascertained 49% and 67% of 
infants born to known compared to newly diagnosed HIV positive women respectively, did not 
receive a PCR test. The number of infants that received their PCR test result is unknown except for 
the infected infants diagnosed at RMMCH.  
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In total, 286 of the 591 (48.4%) HIV-exposed study infants were expected to 
attend the infant testing service at RMMCH (Table 4.7). Table 4.8 shows the 
follow-up and testing rates of these infants. 
 
 
All HIV-
exposed 
Infants 
Infants expected for 
follow-up at RMMCH p-value 
only for 
RMMCH 
tested 
infants 
Infants 
known to be 
exposed 
before arrival 
for delivery 
Infants 
newly 
diagnosed 
as exposed 
perinataly 
Total number 
expected 591 203 83  
Infants PCR tested 
and received 
cotrimoxazole 
284 (48.0%) 155 (76.4%) 12 (14.5%) 
<0.001 
(Chi-square 
test) 
PCR positive 
infants 16 (5.6%) 9 (5.8%) 1 (8.3%) 
0.54 
(Fisher 
exact test) 
 
Table 4.8: Infant Follow-Up Dynamics. Cotrimoxazole prophylaxis was given to infants 
presenting at six weeks for an HIV test at RMMCH and it was assumed that other clinics followed 
the same protocol although this was not checked.  
 
There were 97 PCR results (91 negative, six positive) traced from the NHLS 
database for infants born to women known to be HIV positive before arriving for 
delivery. Twenty results (all negative) were traced for infants born to women newly 
diagnosed by the study protocol. Combining traced results with the PCR results 
done at RMMCH, 32% (32/101) of infants to newly diagnosed mothers had a PCR 
done, although only 14.5% (12/83) of those expected to return to RMMCH arrived 
for PCR testing. 
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Loss to follow-up was a significant problem as 48 (23.6%) of 203 HIV-exposed 
infants identified antenataly and 71 (85.0%) of 83 newly diagnosed HIV-exposed 
infants due for testing at RMMCH did not return there. The rate of return in the 
newly diagnosed group was significantly lower (Table 4.8) showing that follow-up 
after a new maternal HIV diagnosis was poor. As the numbers were small the 
study objective of determining whether transmission rates differed between the 
known and newly diagnosed HIV-positive groups could not be answered. Of the 
ten infants diagnosed at RMMCH as HIV-infected nine were in care and one was 
lost to follow-up. Six infants had been initiated on ART (including the infant from a 
mother newly diagnosed at the time of delivery), two were awaiting ART initiation 
and one was being monitored for need of initiation.  
 
 
4.4.4 Impact on Monitoring and Evaluation: 
 
The RMMCH antenatal attendees formed less than a quarter of the RMMCH 
delivering group (Figure 4.2). This difference between the antenatal population 
and the delivering population at a facility is important because most national 
PMTCT indicators related to the identification of HIV-positive women focus on the 
monitoring of antenatal service delivery, for example antenatal testing rate and 
antenatal prevalence.  
 
The HIV prevalence rate amongst women from different ANC services varied. The 
women attending RMMCH antenatal clinic had an HIV prevalence that was 10% 
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less than those attending the Witkoppen ANC. This demonstrates that the 
population of women attending the RMMCH delivery facility was heterogeneous 
with respect to their HIV risk. The HIV prevalence for the whole group (24.8%) was 
slightly lower than the national and Gauteng figures of 28.0% and 30.3% 
respectively for 2007 [2].  
 
HIV prevalence at delivery is not a routine indicator of the PMTCT dataset. The 
“live births to HIV-positive women” form a subset of the “total live births” but there 
is no provision for distinguishing “live births to HIV-negative women” from “live 
births to women of unknown status” which are the other two subsets of “total live 
births”. A falsely low prevalence results if the number of “live births to HIV-positive 
women” is divided by “total live births” when not all women know their HIV status, 
yet the HIV prevalence at delivery is an important indication of how many infants 
should be receiving treatment and then proceed to infant testing following delivery. 
The HIV prevalence at delivery should not be much lower than the HIV prevalence 
found at antenatal services for the same population. The standard indicator of 
antenatal HIV prevalence versus the delivery HIV prevalence were compared to 
the study group HIV prevalence where 98.6% of women had a known HIV status 
(Figure 4.8). 
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Figure 4.8: HIV Prevalence at RMMCH ANC versus RMMCH Delivery. The ANC HIV prevalence 
in 2008 (blue bars only) was statistically significantly lower than in 2006 (p<0.001). The downward 
trend of RMMCH ANC HIV prevalence is contrasted here with the upward trend of labour ward HIV 
prevalence from 15% to 18.7% (p<0.001). The HIV prevalence in both the labour ward and study 
group were calculated by dividing the number of “live births to HIV-positive women” by “total live 
births” without factoring in the number of women with unknown HIV status. 
   
The downward trend in ANC HIV prevalence could be due to a decreasing 
prevalence in the local antenatal population. The increasing labour ward 
prevalence may reflect improved reporting as a consequence of this study and / or 
the higher HIV prevalence in women from ANC’s other than RMMCH that fed into 
the delivery population. In enrolled women, a quarter of the total 2008 delivering 
population, the proportion of women with known HIV status increased by 10.2% to 
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98.6% between the time of arrival and departure from the delivery service (Figure 
4.6). In 2008 the study HIV prevalence was significantly higher than the labour 
ward prevalence (p<0.001).  
  
Figure 4.9 shows the number of known and additional theoretical number of HIV-
exposed infants. There are potentially three groups of HIV-exposed infants: 1) 
those known to be HIV-exposed before the time of delivery, 2) those newly 
diagnosed as HIV-exposed due to the peripartum testing protocol, 3) those 
expected to be HIV-exposed where the mother refused a test. It was assumed that 
women who refused an HIV test had a high prevalence of 44% [22]. 
 
In PMTCT, “coverage” is defined as the proportion of HIV-exposed infants 
identified who receive appropriate ART. In the RMMCH postnatal ward every 
infant identified as HIV-exposed receives treatment unless the mother refuses. 
Therefore the only HIV-exposed infants who lost their opportunity for PMTCT 
prophylaxis completely are those whose mothers refused an HIV test. Irrespective 
of how many HIV-exposed infants remain unidentified, the reported “coverage” will 
remain 100%. The true “coverage” is that proportion of infants treated when the 
maternal HIV prevalence is extrapolated to include the group of women who 
refuse testing. 
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Figure 4.9: Prevalence and Numbers of HIV-exposed Infants – Coverage Discrepancies. The 
denominator of ‘total number of HIV-exposed infants’ was calculated as follows: Total number of 
HIV-exposed infants found by the time of departure from postnatal service (n=591) plus 44% of the 
women who refused an HIV test (n=33) resulting in a total of 606 expected HIV-exposed infants. 
There was a 17% increase in the true coverage of all HIV-exposed infants following the 
identification of additional HIV-positive mothers.  
 
This provides evidence that a falsely reassuring picture is created if the ANC HIV-
prevalence is assumed to be the prevalence at delivery and if no further HIV 
testing or recalculation of prevalence at the time of delivery is undertaken. 
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Chapter 5: Discussion 
 
5.1 Increased Identification of HIV-positive Women 
 
The study sample, although not random, was likely to be representative of women 
with live births at RMMCH during the study period. A large number (71%) of the 
total delivering population was interviewed and there were no significant 
differences between those enrolled and those interviewed.  Results from the first 
half of the study sample were equivalent to those of the second half.  
 
The proportion of women knowing their HIV status on arrival for delivery, antenatal 
booking distribution and median age were similar in the enrolled versus the 
interviewed population. Consent refusal was the main reason for not enrolling and 
age under 18 years excluded about 5% of women from enrolling. Entry into the 
study was allowed even if an HIV test was refused, therefore there was no reason 
to suspect that the effect of the intervention would be different if applied to all 
interviewed women but HIV-test refusal may have been higher in the women who 
declined to enrol.  
 
Women not interviewed by the counsellors were those discharged on weekend 
afternoons or after the counsellors working hours during the week. High daily 
admission and discharge rates in the postnatal wards suggested that women not 
interviewed due to counsellor working hours were unlikely to differ significantly 
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from those interviewed. There was no reason to believe that those women 
discharged and not interviewed on a weekend or late weekday afternoon would 
have less chance of being HIV-infected. The counsellors interviewed women post-
Caesarean section and after normal delivery irrespective of whether their infants 
were with them in the ward or required admission immediately post-delivery. 
Women that were enrolled in the study were in the same wards as those that 
refused to participate in the study. Although the recruiting process became more 
efficient over time, the actual results remained constant. 
 
To ensure reliable HIV test results, the perception of poorly performing rapid tests 
on the DOH tender was investigated. Used according to the serial testing 
algorithm recommended by the DOH to screen for and then confirm a diagnosis of 
HIV, the rapid tests were 100% sensitive and specific. This information allayed 
fears expressed by nursing and counseling staff regarding reliability of the kits and 
the process of testing according to the DOH algorithm resumed. Validation of the 
algorithm also allowed for confidence in the results of determining HIV status in 
this study. 
 
The study identified significant additional numbers of HIV-positive women 
(p<0.001). For every 25 women who participated in the study one additional HIV 
positive woman and her exposed infant were identified and provided with PMTCT-
related interventions. The 4.2% of the study population newly diagnosed as HIV-
positive is in itself important considering that it is higher than the national antenatal 
prevalence of some African countries (Ghana, Burkina Faso and Senegal) [1]. 
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5.2 Change from HIV-negative to HIV-positive Status 
 
The finding that just under 5% of women reporting an HIV-negative status and 
agreeing to a retest were found to be HIV-positive is alarming, although it is in line 
with previous experience in South Africa [23, 24]. For the 32 HIV-exposed infants 
in this group the transmission rate would have been reduced from 25-40% to 15% 
[15, 16, 17] therefore preventing HIV in three to eight infants. This assumes 
mothers continued administering the PMTCT prophylaxis and practiced their 
intended feeding method. 
 
The significant conversion rate in women reporting an HIV-negative status shows 
that the six week period was a useful cut-off. Since women who tested HIV-
negative more than twelve weeks ago had had more time to become HIV-infected 
than those testing HIV-negative six to twelve weeks ago, it was unexpected that 
the latter group did not have a higher rate of “seroconversion” than the group that 
had an HIV-negative result from six to twelve weeks ago, and this was unlikely to 
be influenced by those that refused a test since the two groups were similar in 
terms of test refusal.  
 
Seroconversion between antenatal care and delivery does not necessarily reflect a 
recent HIV infection but may be accounted for by reporting and documenting 
errors by women or the healthcare service. This could be seen by the fact that the 
negative predictive value of the verbal HIV-negative status with documentation 
was higher than that without documentation. Documentation of the status was 
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more reliable than the woman’s verbal report and could be as a result of denial of 
a positive HIV status.  The highest rates of “seroconversion” were seen in the 
Diepsloot and “Other ANC” groups, the same two groups that had slightly lower 
knowledge of HIV status amongst ANC attendees possibly indicating room for 
improvement in HIV-testing services. It can be concluded though, that HIV 
retesting during later pregnancy and in the peri-partum period is a crucial part of 
PMTCT. Recent literature confirms that HIV incidence during pregnancy is higher 
than outside of pregnancy [38]. Furthermore experience in Botswana has 
demonstrated that when a PMTCT program improves, transmission of HIV from 
infection late in pregnancy and during breastfeeding accounts for almost half of 
vertical transmission [30].  
 
For the 47 women reporting an HIV-negative status but refusing a retest it was not 
possible to determine their status but the group should not be overlooked as 
refusal of an HIV-test has previously been associated with a higher HIV-
prevalence (Smith et al) although this was in women who had never tested before 
[22]. Of the total study group, 33 (1.4%) women were discharged from the 
postnatal ward with an unknown HIV status. Although a small number of women, 
they were at higher risk of being HIV-infected and therefore of having 
proportionately more HIV-exposed infants. Further work is required to devise ways 
of assisting women to test, dealing with specific reasons for refusal and possibly 
offering the infants of these women prophylaxis despite refusal of maternal testing. 
These issues were not investigated in this study and the ethical and public health 
arguments around them are beyond the scope of this discussion. 
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5.3 Newly Diagnosed HIV-negative Women 
 
Although the emphasis is often placed on the identification of HIV-positive women 
during PMTCT-related activities, the most effective way of preventing HIV in 
children is preventing HIV in parents. As health care workers in a postnatal setting 
are primarily focussed on ensuring the protection of the HIV-exposed infant, the 
potential benefit of reinforcing health education and preventative efforts for HIV-
negative women may be overlooked. 
 
During the study, 7.3% of the total study population were newly identified as HIV-
negative. Measuring the potential benefit of this improved “knowledge of HIV 
status” was not within the scope of this study, but the additional focussed 
counseling session that these women received may influence some of their future 
choices. Efforts such as these, that target the first two prongs of the WHO 
strategic approach to PMTCT should not be neglected, and should be 
incorporated into current programs.  
 
 
5.4 Infant PMTCT Access 
 
The issue of infants receiving interventions was inherently linked to the 
identification of new HIV-positive women. All newly identified HIV-exposed infants 
received sdNVP and the first dose of AZT from the nursing staff in the postnatal 
wards. The mothers were counseled on how to administer AZT to their infants and 
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on the importance of correct infant feeding practices. At the time of discharge from 
the postnatal ward it could not be guaranteed that the mother would comply fully 
with AZT administration or exclusive feeding and bring the infant back for a PCR 
test at RMMCH or any health care facility. 
 
Considering that the dual therapy program was launched in April 2008, the 
distribution of PMTCT interventions which women diagnosed antenataly had 
accessed by the time they presented in labour reflected how quickly the AZT 
program had been implemented. Although the majority of women had received 
AZT for less than four weeks, almost a quarter of the mothers had received more 
than four weeks of AZT during their pregnancy. Just over 15% of mothers had 
started triple ART during their pregnancy. One would expect about 15-20% of 
antenatal HIV-positive women to require ART due to low CD4 counts in this setting 
as noted by Coovadia in 2004 [39]. Women attending the antenatal services 
described in this study seemed to be accessing appropriate care if identified as 
being HIV-positive antenataly although there is room for improvement as 5.1% of 
antenataly diagnosed women had not received or taken any prophylaxis by the 
time of delivery. 
 
Infant follow-up of HIV-exposed infants remains a major challenge both nationally 
and at RMMCH with a marked loss to follow-up ranging from 24% of infants known 
to be HIV-exposed by delivery to 70% of HIV-exposed infants born to newly 
diagnosed HIV-positive mothers. One of the most important needs identified in this 
study was that all HIV-positive mothers, particularly those newly diagnosed around 
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delivery, need support in terms of taking the important step towards early infant 
testing. Improved counseling on infant testing and working towards acceptance of 
HIV diagnosis and disclosure may also be needed for both groups. This was 
highlighted by the fact that two mothers in the newly diagnosed group refused 
upfront to administer AZT to their infants and three mothers refused to exclusively 
formula or breastfeed. This showed that although there was benefit to many 
infants, there were a few individual mothers who struggled to accept the HIV-
positive result given to them around the time of delivery. Therefore PMTCT 
programs should allow for additional counseling and support required by newly 
diagnosed HIV-positive women at the time of delivery. 
 
Follow-up of infants was complicated by the fact that the study population seemed 
mobile as evidenced by the number of women delivering at RMMCH having 
booked at ANC services elsewhere in the province. The lack of continuity between 
antenatal, maternal and child health services, due to the vertical nature of the 
PMTCT program, may prevent good communication of HIV results between 
antenatal care and the point of delivery as well as poor infant follow-up.  
 
The majority (93.9%) of HIV-positive mothers stated that they intended to formula 
feed rather than breast feed. A similar trend towards formula feeding had been 
noted in 2002 and 2006 at the same institution [32, 33, 34]. The WHO 
recommends that mothers should be assisted in choosing their preferred feeding 
method while taking into account the AFASS criteria. The overwhelming choice of 
formula feeding raises concerns because many women originated from very poor 
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areas like the squatter camps around Diepsloot. The skewed choice of infant 
feeding practices requires further assessment to establish whether the choices 
women made were well informed and whether quality of infant feeding counseling 
was adequate.  
 
 
5.5 Infant Testing Outcomes 
  
No meaningful comparison of transmission rates in infants of mothers with known 
and newly diagnosed HIV-positive status at delivery was possible because of the 
small number of PCR results available in the latter group. It is highly likely that the 
vertical transmission rate in the HIV-exposed infants identified at birth was 
reduced by the study interventions and that the HIV-exposed but uninfected 
infants benefited e.g. by feeding counseling to minimize postnatal transmission. Of 
the 32 infants born to newly diagnosed HIV-positive women at delivery that were 
tested, one infant was identified as HIV-positive and is currently receiving 
HAART. Identification of HIV positive women at delivery improved access to 
PMTCT prophylaxis for infants but did not translate into identification of these 
infants for early diagnosis in the majority of cases.  
 
For the infants of women known to be HIV-positive by the time of delivery, the 
follow-up for testing was better and the 5.8% transmission rate was in line with 
what has previously been observed at RMMCH. All infected infants except one 
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were in care suggesting that the major challenge lies in getting infants back to 
facilities for testing rather than in the follow-up of confirmed infected infants.  
 
The importance of knowing a negative HIV status, in this case for an infant, should 
not be overlooked because establishing a negative HIV status in an exposed infant 
provides the opportunity to reassure the mother. Further, each contact with the 
health care system is an opportunity to reinforce health education and counseling 
messages for the mother and to provide services such as CD4 counts and 
referrals to adult treatment centres. 
 
 
5.6 Monitoring and Evaluation of the PMTCT Program 
 
Identification of HIV-positive women antenataly allows the indicator of “Antenatal 
HIV prevalence” to be calculated but the study demonstrates that the HIV 
prevalence in the women delivering at RMMCH differed from the antenatal HIV 
prevalence because women from RMMCH ANC only comprise 24% of women 
delivering at RMMCH. Knowledge of HIV status in women from the RMMCH ANC 
compared to the whole delivering population was 99% and 89% respectively on 
arrival for delivery. The study intervention increased knowledge of HIV status by 
10.2% leaving 2% of women without knowledge of their HIV status. The resultant 
HIV-prevalence, which increased by 1.9%, approximates the true prevalence at 
delivery, improves the infant PMTCT coverage significantly and provided a more 
honest measure of PMTCT program efficacy. 
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The variation in knowledge of HIV status between women from different antenatal 
clinics could be a reflection of the quality of testing coverage or counseling at 
these clinics. The wide variation of HIV prevalence between groups of women, 
notably a more than 10% difference between the women who booked at RMMCH 
versus those that booked in clinics that served predominately women from 
informal and poorer settlements (Witkoppen, Diepsloot and Discoverers) reflects 
that HIV-prevalence in communities may be related to socio-economic status. 
 
These findings emphasise the importance of analysing the delivering population 
separately to the antenatal populations in large centres to understand the 
dynamics as well as quality of testing at feeder clinics. It also provides an 
opportunity to strengthen referral systems and communication between facilities 
when this information is fed back to the feeder clinics. This process is ongoing 
between RMMCH and its referral sites. 
 
The setting of RMMCH is that of a well established and well running PMTCT site. 
The improvement noted following this intervention may  be greater in sites with a 
lower baseline of PMTCT service quality as measured by the percentage of 
women arriving for delivery with a known HIV status. To improve the accuracy of 
reporting of the PMTCT program the prevalence for the delivering group should be 
calculated and reported to enable more accurate calculation of the PMTCT 
coverage. Sites where the delivering group is made up largely of the local 
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antenataly booked women and where the antenatal clinic has excellent testing 
rates may not need this intervention. 
 
The cost of this intervention was not measured but involved employment of 
counsellors and performing an increased number of HIV tests. Two full-time 
counsellors managed to cover almost three quarters of the delivering population. 
Employing one counsellor per 3500 deliveries to achieve a 17% or higher 
improvement in PMTCT coverage may prove a cost-effective intervention in a 
country like South Africa with high paediatric and maternal HIV burden. Training 
nursing staff in labour and postnatal wards to counsel and test women after hours 
could increase the benefits of this intervention. 
 
 
5.7 Conclusion 
 
The study intervention revealed beneficial outcomes as well as challenges that 
need to be considered in order to improve the South African PMTCT program. The 
significant number of newly identified HIV-positive mothers should be a prompt for 
similar facilities to engage in testing and retesting around delivery and in this way 
promote active HIV case finding and “re-recruitment” into the PMTCT program at 
the time of birth until such time as either the HIV prevalence drops or antenatal 
care escalates and improves to a level that obviates this need. Both HIV-positive 
and negative women, especially those newly diagnosed at the time of delivery, 
were a captive audience at the time of delivery and could benefit from proactive 
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health care interventions. This intervention improved infant PMTCT coverage by 
identifying a significant number of at-risk infants and providing them with access to 
HIV prophylaxis as well as a link to HIV testing and care. The intervention in itself 
was not ideal as HIV-positive women should be diagnosed in time to receive at 
least four weeks of antenatal AZT and to adjust to their diagnosis. The intervention 
is worthwhile currently though, because with relatively little effort significant 
numbers of HIV-positive and negative women are identified with benefit to 
themselves and their infants.  
 
Routine peri-partum HIV testing and counseling of women in the ante- and 
postnatal wards does improve access to HIV prevention, testing and treatment for 
their infants but does not, in itself, translate into improved outcomes of care for 
HIV-exposed infants because more work is urgently required to find practical ways 
of improving rates of infant follow-up of HIV-exposed infants. Better integration of 
maternal and child health services, for example a Road to Health Card 
documenting HIV-exposure status more clearly or routine screening of infants for 
HIV-exposure at well baby clinics may improve infant care. Other areas that 
require further research into operational interventions include support and 
counseling for HIV-positive women, particularly those newly diagnosed as HIV-
positive during late pregnancy or the peri-partum period. Feeding counseling and 
practices also need further attention. The peripartum counselling and testing 
protocol ensures that PMTCT coverage is reported more accurately which is a 
necessary step in improving PMTCT efficacy and working towards eradication of 
paediatric HIV.
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Appendix A – Ward Register 
 
Name                   
Surname 
Mother 
DoB* 
dd/mm/yyyy Booking Status reported by mother 
Status on ANC card or in file (pls 
double check) 
Testing 
now? 
Lab 
no Rslt† 
PMTCT med 
To MOTHER 
PMTCT 
med To 
BABY 
If 
positive 
- 
Transfer 
out?‡ 
If positive - 
Feeding 
Choice 
    
Bookd 
where 
Positive Negative, tested less than 6 wks ago  Positive 
Negative, tested less 
than 6 wks ago  Not needed   
 P / N / 
Err 
sdNVP /                                
sdNVP+AZT 
for __ wks / 
ART for 
____wks /                       
None 
sdNVP + 
AZT for                          
1 week /              
4 weeks 
Y………
/ N 
Breast / 
Formula 
Unbooked Unknown 
Negative 6-12 
weeks ago / >12 
wks ago 
Unknown Negative 6-12 weeks 
ago / >12 wks ago Yes Refusd   
 P / N / 
Err 
    
Bookd 
where 
Positive Negative, tested less than 6 wks ago  Positive 
Negative, tested less 
than 6 wks ago  Not needed   
 P / N / 
Err 
sdNVP /          
sdNVP+AZT 
for __ wks / 
ART for 
____wks /                       
None 
sdNVP + 
AZT for                          
1 week /              
4 weeks 
Y………
/ N 
Breast / 
Formula 
Unbooked Unknown 
Negative 6-12 
weeks ago / >12 
wks ago 
Unknown Negative 6-12 weeks 
ago / >12 wks ago Yes Refusd   
 P / N / 
Err 
    
Bookd 
where 
Positive Negative, tested less than 6 wks ago  Positive 
Negative, tested less 
than 6 wks ago  Not needed   
 P / N / 
Err 
sdNVP /                                
sdNVP+AZT 
for __ wks / 
ART for 
____wks /                       
None 
sdNVP + 
AZT for                          
1 week /              
4 weeks 
Y………
/ N 
Breast / 
Formula 
Unbooked Unknown 
Negative 6-12 
weeks ago / >12 
wks ago 
Unknown Negative 6-12 weeks 
ago / >12 wks ago Yes Refusd   
 P / N / 
Err 
    
Bookd 
where 
Positive Negative, tested less than 6 wks ago  Positive 
Negative, tested less 
than 6 wks ago  Not needed   
 P / N / 
Err 
sdNVP /                                
sdNVP+AZT 
for __ wks / 
ART for 
____wks /            
None 
sdNVP + 
AZT for                          
1 week /              
4 weeks 
Y………
/ N 
Breast / 
Formula 
Unbooked Unknown 
Negative 6-12 
weeks ago / >12 
wks ago 
Unknown Negative 6-12 weeks 
ago / >12 wks ago Yes Refusd   
 P / N / 
Err 
                                                           
*
 DoB = Date of Birth 
†
 Result:  P = Positive; N = Negative; Err = Error 
‡
 Relates to where the mother intends to have her HIV-exposed infant tested, either at RMMCH (N) or at another clinic (Y and name of clinic) 
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Appendix B – Study and HIV testing Consent form 
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Name and signature of person who obtained informed consent: ……………..……………………………………… 
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Appendix C – HIV consent for women not participating in study (in routine 
use at RMMCH) 
Informed Consent for HIV Testing of Adults 
Coronation Woman and Children Hospital 
 
MINIMUM PROCEDURE FOR OBTANING INFORMED CONSENT FOR HIV TESTING 
Date: ______________    Name: _______________ 
 
EXPLANATORY NOTES FOR CARE WORKERS 
 
1. WHAT IS INFORMED CONSENT? 
 Informed consent is the legal requirement that is necessary before a doctor or other health care worker 
examines, investigates or manages a patient. 
2. INFORMED CONSENT FOR HIV TESTING MUST BE SPECIFIC AND EXPLICIT  
  Consent to HIV testing is not covered by the usual contractual agreement which is implied when a patient 
consult a doctor. The reason is that the implications of a positive test in the present social climate may be 
extreme, (This may change as attitude to and Knowledge and understanding of HIV infection changes). 
3. WHAT DOES INFORMED CONSENT IMPLY IN THE CONTEXT OF HIV TESTING 
Informed consent implies that the patient has received minimum of the pre-test information and counseling and 
understanding the following 
 The reason or purpose for which the test is being performed. 
 The potential advantages of having his/her status determined, especially access of treatment 
 The influence the results of the HIV test may have on treatment. 
 The possible psycho-social impact of a positive test. 
POST TEST COUNSELING 
The principle of informed consent implies tat once the patient’s test is known (positive or negative) appropriate counselling 
will follow. The health care worker should therefore ensure that the positive patients are directed to appropriate facilities 
where they will receive ongoing care and management. 
DOCUMENTATION 
It is recommended that a note be made in the patient’s file/record that informed consent for HIV has been obtained and 
from whom. 
EXPLANATORY NOTES FOR PERSONS OFFERED AN HIV TEST  
TESTING 
1. I / We / the health care worker(s) wishes to test you for HIV infection- Your consent (permission) is requested to do 
so. 
2. This is a test on your blood which will establish whether or not you have been infected with the virus, called HIV, 
which may cause AIDS. 
3. The reason(s) I want this test performed is/are 
3.1. To help me diagnose your illness 
3.2. To help me give the proper treatment 
3.3. In the context of pregnancy, we would like to offer you access to further health care if you are found to be 
HIV-positive as well as help to keep your status HIV-negative if you are found to be HIV-negative. 
3.4. If you have just had a baby and you are HIV-positive we would like to offer you and/or your baby 
preventative medicine to prevent the baby becoming HIV infected.  
 Because you asked to be tested for HIV infection 
4. If the test is positive, treatment may have to be modified in your own interest. (Treatment should not be sub-
optimal because of any perceived potential risk to the health care worker) 
5. You should realize now that if the test shows you to be HIV-positive this means that:-    
 Your results will be treated with confidentiality 
 You may be able to make changes to your lifestyle, which will improve your quality of life 
 You are at risk of developing AIDS which at present can be treated but cannot yet be cured. 
 You may suffer discrimination in obtaining work, insurance and medical aid 
 Knowledge of your positive status will allow the heath care worker to proceed to screen you for treatment with 
effective Anti retroviral therapy. 
 Knowledge of your status as a new mother may help us to protect your baby from becoming HIV-positive. 
6. A negative test is not an absolute guarantee that you are not infected. 
SIGNATURE (PATIENT)                      __________________________   pre-test 
SIGNATURE (HEALTH WORKER)    ___________________________    
 
SIGNATURE (PATIENT)                      __________________________   post-test 
SIGNATURE (HEALTH WORKER)    ___________________________    
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